CAG regimen for refractory or relapsed adult T‐cell acute lymphoblastic leukemia: A retrospective, multicenter, cohort study
Adult patients with relapsed or refractory T‐cell acute lymphoblastic leukemia (R/R‐T‐ALL) have extremely poor prognosis, representing an urgent unmet medical need. Finding an optimal salvage regimen to bridge transplantation is a priority. The CAG (cytarabine, aclarubicin, and G‐CSF) regimen was in...
Gespeichert in:
| Veröffentlicht in: | Cancer Medicine 2020-08, Vol.9 (15), p.5327-5334 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 5334 |
|---|---|
| container_issue | 15 |
| container_start_page | 5327 |
| container_title | Cancer Medicine |
| container_volume | 9 |
| creator | Qian, Jie‐Jing Hu, Xiaoxia Wang, Ying Zhang, Yi Du, Juan Yang, Min Tong, Hongyan Qian, Wen‐Bin Wei, Juying Yu, Wenjun Lou, Yin‐Jun Mao, Liping Tao Meng, Hai You, Liang‐Shun Wang, Libing Li, Xia Huang, Xin Cao, Li‐Hong Zhao, Jian‐Zhi Yan Yan, Xiao Chen, Yu‐Bao Chen, Yu Zhang, Su‐Jiang Jin, Jie Hu, Jiong Zhu, Hong‐Hu |
| description | Adult patients with relapsed or refractory T‐cell acute lymphoblastic leukemia (R/R‐T‐ALL) have extremely poor prognosis, representing an urgent unmet medical need. Finding an optimal salvage regimen to bridge transplantation is a priority. The CAG (cytarabine, aclarubicin, and G‐CSF) regimen was initially used by one group in China, showing unexpectedly promising results in 11 R/R‐T‐ALL patients. Here, we report the multicenter results of 41 patients who received the CAG regimen as salvage therapy. After one cycle of the CAG regimen, complete remission and partial remission were achieved in 33 (80.5%) and two (4.9%) patients, respectively. Failure to respond was observed in six patients (14.6%). Early T‐cell precursor (ETP) (n = 26) and non‐ETP (n = 15) patients had a similar CR rate (80.8% vs 80.0%, P = .95). Among 41 patients, allo‐HSCT was successfully performed in 27 (66%) patients (22 in CR and 5 in non‐CR). With a median follow‐up time of 12 months, the estimated 2‐year overall survival and event‐free survival were 68.8% (95% CI, 47.3%‐83.0%) and 56.5% (95% CI, 37.1%‐71.9%), respectively. The CAG regimen was well‐tolerated, and no early death occurred. Our multicenter results show that the CAG regimen is highly effective and safe, representing a novel choice for adult patients with R/R‐T‐ALL and providing a better bridge to transplantation.
Adult patients with relapsed or refractory T‐cell acute lymphoblastic leukemia (R/R‐T‐ALL) have limited therapeutic options and extremely poor prognosis (CR rate |
| doi_str_mv | 10.1002/cam4.3079 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_webof</sourceid><recordid>TN_cdi_webofscience_primary_000537250500001</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A710523630</galeid><doaj_id>oai_doaj_org_article_9b330939c9c64908b80504eb376b9ac6</doaj_id><sourcerecordid>A710523630</sourcerecordid><originalsourceid>FETCH-LOGICAL-c6049-2837689f1ce1a590e6c529e584cbecb409fb005e20af9494a0d68af5689d2a8a3</originalsourceid><addsrcrecordid>eNqNksFu1DAQhiMEolXpgRdAkbiA6G4d20lsDkirCEqlIi7lbDnOZNcliRfbKdoL4hF4Rp6Eye6yapFAOIc4zvf_mn88SfI0I_OMEHpudM_njJTyQXJMCc9nZcH4wzv7o-Q0hBuCqyS0KLPHyRGjXFIq5HHyrVpcpB6WtochbZ3Hfeu1ic5v0u1Xp9cBmlQ3YxfT65_ffxjoulSbMULabfr1ytWdDtGatIPxM_RWv04XqIvehTWYaG_hLO1RbA0MEfxZatzK-ZiGODabJ8mjVncBTvfvk-TTu7fX1fvZ1ceLy2pxNTMF4XJGBSsLIdvMQKZzSaAwOZWQC25qMDUnsq0JyYES3UouuSZNIXSbo6ahWmh2klzufBunb9Ta2177jXLaqu2B80ulPZbYgZI1Y0QyaaQpuCSiFiQnHGqsoJbaFOj1Zue1HusemimW19090_t_BrtSS3erSk6oyAQavNgbePdlhBBVb8PUVj2AG4OimKfgGFMi-vwP9MaNfsBWIYVIWeQ8-zfFSCYEzSav-Y5aaoxph9ZhdQafBm_NuAFai-eLMiM5ZQUjKHi5Exi8y4CDcciYETXNnppmT02zh-yzu005kL8nDYFXO-Ar1K4NxsJg4IDhcOaspDm2GteUSPw_Xdmoo3VD5cYhovR8L8U4m7-XrKrFB76t_RcyVAPk</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2430188219</pqid></control><display><type>article</type><title>CAG regimen for refractory or relapsed adult T‐cell acute lymphoblastic leukemia: A retrospective, multicenter, cohort study</title><source>Wiley Online Library - AutoHoldings Journals</source><source>DOAJ Directory of Open Access Journals</source><source>Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library (Open Access Collection)</source><source>PubMed Central</source><creator>Qian, Jie‐Jing ; Hu, Xiaoxia ; Wang, Ying ; Zhang, Yi ; Du, Juan ; Yang, Min ; Tong, Hongyan ; Qian, Wen‐Bin ; Wei, Juying ; Yu, Wenjun ; Lou, Yin‐Jun ; Mao, Liping ; Tao Meng, Hai ; You, Liang‐Shun ; Wang, Libing ; Li, Xia ; Huang, Xin ; Cao, Li‐Hong ; Zhao, Jian‐Zhi ; Yan Yan, Xiao ; Chen, Yu‐Bao ; Chen, Yu ; Zhang, Su‐Jiang ; Jin, Jie ; Hu, Jiong ; Zhu, Hong‐Hu</creator><creatorcontrib>Qian, Jie‐Jing ; Hu, Xiaoxia ; Wang, Ying ; Zhang, Yi ; Du, Juan ; Yang, Min ; Tong, Hongyan ; Qian, Wen‐Bin ; Wei, Juying ; Yu, Wenjun ; Lou, Yin‐Jun ; Mao, Liping ; Tao Meng, Hai ; You, Liang‐Shun ; Wang, Libing ; Li, Xia ; Huang, Xin ; Cao, Li‐Hong ; Zhao, Jian‐Zhi ; Yan Yan, Xiao ; Chen, Yu‐Bao ; Chen, Yu ; Zhang, Su‐Jiang ; Jin, Jie ; Hu, Jiong ; Zhu, Hong‐Hu</creatorcontrib><description>Adult patients with relapsed or refractory T‐cell acute lymphoblastic leukemia (R/R‐T‐ALL) have extremely poor prognosis, representing an urgent unmet medical need. Finding an optimal salvage regimen to bridge transplantation is a priority. The CAG (cytarabine, aclarubicin, and G‐CSF) regimen was initially used by one group in China, showing unexpectedly promising results in 11 R/R‐T‐ALL patients. Here, we report the multicenter results of 41 patients who received the CAG regimen as salvage therapy. After one cycle of the CAG regimen, complete remission and partial remission were achieved in 33 (80.5%) and two (4.9%) patients, respectively. Failure to respond was observed in six patients (14.6%). Early T‐cell precursor (ETP) (n = 26) and non‐ETP (n = 15) patients had a similar CR rate (80.8% vs 80.0%, P = .95). Among 41 patients, allo‐HSCT was successfully performed in 27 (66%) patients (22 in CR and 5 in non‐CR). With a median follow‐up time of 12 months, the estimated 2‐year overall survival and event‐free survival were 68.8% (95% CI, 47.3%‐83.0%) and 56.5% (95% CI, 37.1%‐71.9%), respectively. The CAG regimen was well‐tolerated, and no early death occurred. Our multicenter results show that the CAG regimen is highly effective and safe, representing a novel choice for adult patients with R/R‐T‐ALL and providing a better bridge to transplantation.
Adult patients with relapsed or refractory T‐cell acute lymphoblastic leukemia (R/R‐T‐ALL) have limited therapeutic options and extremely poor prognosis (CR rate <50% and long‐term survival <20%), which represents an urgent and unmet medical need. Finding an optimal salvage regimen that has a good response and is well‐tolerated to bridge to transplantation is a priority.</description><identifier>ISSN: 2045-7634</identifier><identifier>EISSN: 2045-7634</identifier><identifier>DOI: 10.1002/cam4.3079</identifier><identifier>PMID: 32492289</identifier><language>eng</language><publisher>HOBOKEN: Wiley</publisher><subject>Acute lymphoblastic leukemia ; Acute lymphocytic leukemia ; Analysis ; Antimitotic agents ; Antineoplastic agents ; Bone marrow ; Cancer ; Care and treatment ; Chemotherapy ; Clinical Cancer Research ; Cohort analysis ; Cytarabine ; Granulocytes ; Leukemia ; Life Sciences & Biomedicine ; Lymphatic leukemia ; Neutropenia ; Oncology ; Oncology, Experimental ; Original Research ; Prognosis ; refractory or relapse ; Remission ; Science & Technology ; Stem cell transplantation ; Stem cells ; T cells ; Trinucleotide repeats ; T‐cell acute lymphoblastic leukemia</subject><ispartof>Cancer Medicine, 2020-08, Vol.9 (15), p.5327-5334</ispartof><rights>2020 The Authors. published by John Wiley & Sons Ltd</rights><rights>2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.</rights><rights>COPYRIGHT 2020 John Wiley & Sons, Inc.</rights><rights>2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>8</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000537250500001</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c6049-2837689f1ce1a590e6c529e584cbecb409fb005e20af9494a0d68af5689d2a8a3</citedby><cites>FETCH-LOGICAL-c6049-2837689f1ce1a590e6c529e584cbecb409fb005e20af9494a0d68af5689d2a8a3</cites><orcidid>0000-0003-2538-4007 ; 0000-0003-2343-0436 ; 0000-0002-2719-3805 ; 0000-0002-8166-9915</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402818/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402818/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,865,886,1418,2103,2115,11567,27929,27930,28253,45579,45580,46057,46481,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32492289$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Qian, Jie‐Jing</creatorcontrib><creatorcontrib>Hu, Xiaoxia</creatorcontrib><creatorcontrib>Wang, Ying</creatorcontrib><creatorcontrib>Zhang, Yi</creatorcontrib><creatorcontrib>Du, Juan</creatorcontrib><creatorcontrib>Yang, Min</creatorcontrib><creatorcontrib>Tong, Hongyan</creatorcontrib><creatorcontrib>Qian, Wen‐Bin</creatorcontrib><creatorcontrib>Wei, Juying</creatorcontrib><creatorcontrib>Yu, Wenjun</creatorcontrib><creatorcontrib>Lou, Yin‐Jun</creatorcontrib><creatorcontrib>Mao, Liping</creatorcontrib><creatorcontrib>Tao Meng, Hai</creatorcontrib><creatorcontrib>You, Liang‐Shun</creatorcontrib><creatorcontrib>Wang, Libing</creatorcontrib><creatorcontrib>Li, Xia</creatorcontrib><creatorcontrib>Huang, Xin</creatorcontrib><creatorcontrib>Cao, Li‐Hong</creatorcontrib><creatorcontrib>Zhao, Jian‐Zhi</creatorcontrib><creatorcontrib>Yan Yan, Xiao</creatorcontrib><creatorcontrib>Chen, Yu‐Bao</creatorcontrib><creatorcontrib>Chen, Yu</creatorcontrib><creatorcontrib>Zhang, Su‐Jiang</creatorcontrib><creatorcontrib>Jin, Jie</creatorcontrib><creatorcontrib>Hu, Jiong</creatorcontrib><creatorcontrib>Zhu, Hong‐Hu</creatorcontrib><title>CAG regimen for refractory or relapsed adult T‐cell acute lymphoblastic leukemia: A retrospective, multicenter, cohort study</title><title>Cancer Medicine</title><addtitle>CANCER MED-US</addtitle><addtitle>Cancer Med</addtitle><description>Adult patients with relapsed or refractory T‐cell acute lymphoblastic leukemia (R/R‐T‐ALL) have extremely poor prognosis, representing an urgent unmet medical need. Finding an optimal salvage regimen to bridge transplantation is a priority. The CAG (cytarabine, aclarubicin, and G‐CSF) regimen was initially used by one group in China, showing unexpectedly promising results in 11 R/R‐T‐ALL patients. Here, we report the multicenter results of 41 patients who received the CAG regimen as salvage therapy. After one cycle of the CAG regimen, complete remission and partial remission were achieved in 33 (80.5%) and two (4.9%) patients, respectively. Failure to respond was observed in six patients (14.6%). Early T‐cell precursor (ETP) (n = 26) and non‐ETP (n = 15) patients had a similar CR rate (80.8% vs 80.0%, P = .95). Among 41 patients, allo‐HSCT was successfully performed in 27 (66%) patients (22 in CR and 5 in non‐CR). With a median follow‐up time of 12 months, the estimated 2‐year overall survival and event‐free survival were 68.8% (95% CI, 47.3%‐83.0%) and 56.5% (95% CI, 37.1%‐71.9%), respectively. The CAG regimen was well‐tolerated, and no early death occurred. Our multicenter results show that the CAG regimen is highly effective and safe, representing a novel choice for adult patients with R/R‐T‐ALL and providing a better bridge to transplantation.
Adult patients with relapsed or refractory T‐cell acute lymphoblastic leukemia (R/R‐T‐ALL) have limited therapeutic options and extremely poor prognosis (CR rate <50% and long‐term survival <20%), which represents an urgent and unmet medical need. Finding an optimal salvage regimen that has a good response and is well‐tolerated to bridge to transplantation is a priority.</description><subject>Acute lymphoblastic leukemia</subject><subject>Acute lymphocytic leukemia</subject><subject>Analysis</subject><subject>Antimitotic agents</subject><subject>Antineoplastic agents</subject><subject>Bone marrow</subject><subject>Cancer</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Clinical Cancer Research</subject><subject>Cohort analysis</subject><subject>Cytarabine</subject><subject>Granulocytes</subject><subject>Leukemia</subject><subject>Life Sciences & Biomedicine</subject><subject>Lymphatic leukemia</subject><subject>Neutropenia</subject><subject>Oncology</subject><subject>Oncology, Experimental</subject><subject>Original Research</subject><subject>Prognosis</subject><subject>refractory or relapse</subject><subject>Remission</subject><subject>Science & Technology</subject><subject>Stem cell transplantation</subject><subject>Stem cells</subject><subject>T cells</subject><subject>Trinucleotide repeats</subject><subject>T‐cell acute lymphoblastic leukemia</subject><issn>2045-7634</issn><issn>2045-7634</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>AOWDO</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNksFu1DAQhiMEolXpgRdAkbiA6G4d20lsDkirCEqlIi7lbDnOZNcliRfbKdoL4hF4Rp6Eye6yapFAOIc4zvf_mn88SfI0I_OMEHpudM_njJTyQXJMCc9nZcH4wzv7o-Q0hBuCqyS0KLPHyRGjXFIq5HHyrVpcpB6WtochbZ3Hfeu1ic5v0u1Xp9cBmlQ3YxfT65_ffxjoulSbMULabfr1ytWdDtGatIPxM_RWv04XqIvehTWYaG_hLO1RbA0MEfxZatzK-ZiGODabJ8mjVncBTvfvk-TTu7fX1fvZ1ceLy2pxNTMF4XJGBSsLIdvMQKZzSaAwOZWQC25qMDUnsq0JyYES3UouuSZNIXSbo6ahWmh2klzufBunb9Ta2177jXLaqu2B80ulPZbYgZI1Y0QyaaQpuCSiFiQnHGqsoJbaFOj1Zue1HusemimW19090_t_BrtSS3erSk6oyAQavNgbePdlhBBVb8PUVj2AG4OimKfgGFMi-vwP9MaNfsBWIYVIWeQ8-zfFSCYEzSav-Y5aaoxph9ZhdQafBm_NuAFai-eLMiM5ZQUjKHi5Exi8y4CDcciYETXNnppmT02zh-yzu005kL8nDYFXO-Ar1K4NxsJg4IDhcOaspDm2GteUSPw_Xdmoo3VD5cYhovR8L8U4m7-XrKrFB76t_RcyVAPk</recordid><startdate>202008</startdate><enddate>202008</enddate><creator>Qian, Jie‐Jing</creator><creator>Hu, Xiaoxia</creator><creator>Wang, Ying</creator><creator>Zhang, Yi</creator><creator>Du, Juan</creator><creator>Yang, Min</creator><creator>Tong, Hongyan</creator><creator>Qian, Wen‐Bin</creator><creator>Wei, Juying</creator><creator>Yu, Wenjun</creator><creator>Lou, Yin‐Jun</creator><creator>Mao, Liping</creator><creator>Tao Meng, Hai</creator><creator>You, Liang‐Shun</creator><creator>Wang, Libing</creator><creator>Li, Xia</creator><creator>Huang, Xin</creator><creator>Cao, Li‐Hong</creator><creator>Zhao, Jian‐Zhi</creator><creator>Yan Yan, Xiao</creator><creator>Chen, Yu‐Bao</creator><creator>Chen, Yu</creator><creator>Zhang, Su‐Jiang</creator><creator>Jin, Jie</creator><creator>Hu, Jiong</creator><creator>Zhu, Hong‐Hu</creator><general>Wiley</general><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IAO</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-2538-4007</orcidid><orcidid>https://orcid.org/0000-0003-2343-0436</orcidid><orcidid>https://orcid.org/0000-0002-2719-3805</orcidid><orcidid>https://orcid.org/0000-0002-8166-9915</orcidid></search><sort><creationdate>202008</creationdate><title>CAG regimen for refractory or relapsed adult T‐cell acute lymphoblastic leukemia: A retrospective, multicenter, cohort study</title><author>Qian, Jie‐Jing ; Hu, Xiaoxia ; Wang, Ying ; Zhang, Yi ; Du, Juan ; Yang, Min ; Tong, Hongyan ; Qian, Wen‐Bin ; Wei, Juying ; Yu, Wenjun ; Lou, Yin‐Jun ; Mao, Liping ; Tao Meng, Hai ; You, Liang‐Shun ; Wang, Libing ; Li, Xia ; Huang, Xin ; Cao, Li‐Hong ; Zhao, Jian‐Zhi ; Yan Yan, Xiao ; Chen, Yu‐Bao ; Chen, Yu ; Zhang, Su‐Jiang ; Jin, Jie ; Hu, Jiong ; Zhu, Hong‐Hu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c6049-2837689f1ce1a590e6c529e584cbecb409fb005e20af9494a0d68af5689d2a8a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Acute lymphoblastic leukemia</topic><topic>Acute lymphocytic leukemia</topic><topic>Analysis</topic><topic>Antimitotic agents</topic><topic>Antineoplastic agents</topic><topic>Bone marrow</topic><topic>Cancer</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Clinical Cancer Research</topic><topic>Cohort analysis</topic><topic>Cytarabine</topic><topic>Granulocytes</topic><topic>Leukemia</topic><topic>Life Sciences & Biomedicine</topic><topic>Lymphatic leukemia</topic><topic>Neutropenia</topic><topic>Oncology</topic><topic>Oncology, Experimental</topic><topic>Original Research</topic><topic>Prognosis</topic><topic>refractory or relapse</topic><topic>Remission</topic><topic>Science & Technology</topic><topic>Stem cell transplantation</topic><topic>Stem cells</topic><topic>T cells</topic><topic>Trinucleotide repeats</topic><topic>T‐cell acute lymphoblastic leukemia</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Qian, Jie‐Jing</creatorcontrib><creatorcontrib>Hu, Xiaoxia</creatorcontrib><creatorcontrib>Wang, Ying</creatorcontrib><creatorcontrib>Zhang, Yi</creatorcontrib><creatorcontrib>Du, Juan</creatorcontrib><creatorcontrib>Yang, Min</creatorcontrib><creatorcontrib>Tong, Hongyan</creatorcontrib><creatorcontrib>Qian, Wen‐Bin</creatorcontrib><creatorcontrib>Wei, Juying</creatorcontrib><creatorcontrib>Yu, Wenjun</creatorcontrib><creatorcontrib>Lou, Yin‐Jun</creatorcontrib><creatorcontrib>Mao, Liping</creatorcontrib><creatorcontrib>Tao Meng, Hai</creatorcontrib><creatorcontrib>You, Liang‐Shun</creatorcontrib><creatorcontrib>Wang, Libing</creatorcontrib><creatorcontrib>Li, Xia</creatorcontrib><creatorcontrib>Huang, Xin</creatorcontrib><creatorcontrib>Cao, Li‐Hong</creatorcontrib><creatorcontrib>Zhao, Jian‐Zhi</creatorcontrib><creatorcontrib>Yan Yan, Xiao</creatorcontrib><creatorcontrib>Chen, Yu‐Bao</creatorcontrib><creatorcontrib>Chen, Yu</creatorcontrib><creatorcontrib>Zhang, Su‐Jiang</creatorcontrib><creatorcontrib>Jin, Jie</creatorcontrib><creatorcontrib>Hu, Jiong</creatorcontrib><creatorcontrib>Zhu, Hong‐Hu</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale Academic OneFile</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Cancer Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Qian, Jie‐Jing</au><au>Hu, Xiaoxia</au><au>Wang, Ying</au><au>Zhang, Yi</au><au>Du, Juan</au><au>Yang, Min</au><au>Tong, Hongyan</au><au>Qian, Wen‐Bin</au><au>Wei, Juying</au><au>Yu, Wenjun</au><au>Lou, Yin‐Jun</au><au>Mao, Liping</au><au>Tao Meng, Hai</au><au>You, Liang‐Shun</au><au>Wang, Libing</au><au>Li, Xia</au><au>Huang, Xin</au><au>Cao, Li‐Hong</au><au>Zhao, Jian‐Zhi</au><au>Yan Yan, Xiao</au><au>Chen, Yu‐Bao</au><au>Chen, Yu</au><au>Zhang, Su‐Jiang</au><au>Jin, Jie</au><au>Hu, Jiong</au><au>Zhu, Hong‐Hu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CAG regimen for refractory or relapsed adult T‐cell acute lymphoblastic leukemia: A retrospective, multicenter, cohort study</atitle><jtitle>Cancer Medicine</jtitle><stitle>CANCER MED-US</stitle><addtitle>Cancer Med</addtitle><date>2020-08</date><risdate>2020</risdate><volume>9</volume><issue>15</issue><spage>5327</spage><epage>5334</epage><pages>5327-5334</pages><issn>2045-7634</issn><eissn>2045-7634</eissn><abstract>Adult patients with relapsed or refractory T‐cell acute lymphoblastic leukemia (R/R‐T‐ALL) have extremely poor prognosis, representing an urgent unmet medical need. Finding an optimal salvage regimen to bridge transplantation is a priority. The CAG (cytarabine, aclarubicin, and G‐CSF) regimen was initially used by one group in China, showing unexpectedly promising results in 11 R/R‐T‐ALL patients. Here, we report the multicenter results of 41 patients who received the CAG regimen as salvage therapy. After one cycle of the CAG regimen, complete remission and partial remission were achieved in 33 (80.5%) and two (4.9%) patients, respectively. Failure to respond was observed in six patients (14.6%). Early T‐cell precursor (ETP) (n = 26) and non‐ETP (n = 15) patients had a similar CR rate (80.8% vs 80.0%, P = .95). Among 41 patients, allo‐HSCT was successfully performed in 27 (66%) patients (22 in CR and 5 in non‐CR). With a median follow‐up time of 12 months, the estimated 2‐year overall survival and event‐free survival were 68.8% (95% CI, 47.3%‐83.0%) and 56.5% (95% CI, 37.1%‐71.9%), respectively. The CAG regimen was well‐tolerated, and no early death occurred. Our multicenter results show that the CAG regimen is highly effective and safe, representing a novel choice for adult patients with R/R‐T‐ALL and providing a better bridge to transplantation.
Adult patients with relapsed or refractory T‐cell acute lymphoblastic leukemia (R/R‐T‐ALL) have limited therapeutic options and extremely poor prognosis (CR rate <50% and long‐term survival <20%), which represents an urgent and unmet medical need. Finding an optimal salvage regimen that has a good response and is well‐tolerated to bridge to transplantation is a priority.</abstract><cop>HOBOKEN</cop><pub>Wiley</pub><pmid>32492289</pmid><doi>10.1002/cam4.3079</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-2538-4007</orcidid><orcidid>https://orcid.org/0000-0003-2343-0436</orcidid><orcidid>https://orcid.org/0000-0002-2719-3805</orcidid><orcidid>https://orcid.org/0000-0002-8166-9915</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2045-7634 |
| ispartof | Cancer Medicine, 2020-08, Vol.9 (15), p.5327-5334 |
| issn | 2045-7634 2045-7634 |
| language | eng |
| recordid | cdi_webofscience_primary_000537250500001 |
| source | Wiley Online Library - AutoHoldings Journals; DOAJ Directory of Open Access Journals; Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; EZB-FREE-00999 freely available EZB journals; Wiley Online Library (Open Access Collection); PubMed Central |
| subjects | Acute lymphoblastic leukemia Acute lymphocytic leukemia Analysis Antimitotic agents Antineoplastic agents Bone marrow Cancer Care and treatment Chemotherapy Clinical Cancer Research Cohort analysis Cytarabine Granulocytes Leukemia Life Sciences & Biomedicine Lymphatic leukemia Neutropenia Oncology Oncology, Experimental Original Research Prognosis refractory or relapse Remission Science & Technology Stem cell transplantation Stem cells T cells Trinucleotide repeats T‐cell acute lymphoblastic leukemia |
| title | CAG regimen for refractory or relapsed adult T‐cell acute lymphoblastic leukemia: A retrospective, multicenter, cohort study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T04%3A08%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CAG%20regimen%20for%20refractory%20or%20relapsed%20adult%20T%E2%80%90cell%20acute%20lymphoblastic%20leukemia:%20A%20retrospective,%20multicenter,%20cohort%20study&rft.jtitle=Cancer%20Medicine&rft.au=Qian,%20Jie%E2%80%90Jing&rft.date=2020-08&rft.volume=9&rft.issue=15&rft.spage=5327&rft.epage=5334&rft.pages=5327-5334&rft.issn=2045-7634&rft.eissn=2045-7634&rft_id=info:doi/10.1002/cam4.3079&rft_dat=%3Cgale_webof%3EA710523630%3C/gale_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2430188219&rft_id=info:pmid/32492289&rft_galeid=A710523630&rft_doaj_id=oai_doaj_org_article_9b330939c9c64908b80504eb376b9ac6&rfr_iscdi=true |